Beranda › Leukemia Mieloid Akut › New York › Queens
Uji klinis Leukemia Mieloid Akut di Queens, NY
21 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Queens (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- Northwell Health/Center for Advanced Medicine, Lake Success · 9 mi jauhnya
- Memorial Sloan Kettering Nassau, Uniondale · 13 mi jauhnya
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Queens Hospital Center, Jamaica · 2 mi jauhnya
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Menerima pesertaFase 1
- Memorial Sloan Kettering Nassau, Uniondale · 13 mi jauhnya
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau, Uniondale · 13 mi jauhnya
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau, Uniondale · 13 mi jauhnya
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- Northwell Health/Center for Advanced Medicine, Lake Success · 9 mi jauhnya
- Memorial Sloan Kettering Nassau, Uniondale · 13 mi jauhnya
A Study of CRD3874-SI in People With Leukemia
Menerima pesertaFase 1
- Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre · 10 mi jauhnya
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- Northwell Health/Center for Advanced Medicine, Lake Success · 9 mi jauhnya
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Menerima pesertaFase 3
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park · 9 mi jauhnya
- NYU Langone Hospital - Long Island, Mineola · 11 mi jauhnya
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Menerima pesertaFase 2
- Clinical Research Allicance, Westbury · 14 mi jauhnya
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park · 9 mi jauhnya
- NYU Langone Hospital - Long Island, Mineola · 11 mi jauhnya
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Menerima pesertaFase 3
- Cohen Children's Medical Center, Queens
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Menerima pesertaFase 1
- Northwell Health, LLC PRIME, Lake Success · 9 mi jauhnya
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre · 10 mi jauhnya
A Study of Revumenib and Mezigdomide in People With Leukemia
Menerima pesertaFase 1/2
- Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre · 10 mi jauhnya
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Menerima pesertaFase 1
- Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre · 10 mi jauhnya
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Menerima pesertaFase 1
- Memorial Sloan Kettering Nassau, Uniondale · 13 mi jauhnya
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Menerima pesertaFase 1
- Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre · 10 mi jauhnya
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Menerima pesertaFase 2/3
- New York University Langone Hospital - Long Island, Mineola · 11 mi jauhnya
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Menerima pesertaFase 1
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · 13 mi jauhnya
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Menerima pesertaFase 2
- Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre · 10 mi jauhnya
Uji klinis Leukemia Mieloid Akut di kota lain
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Seattle, WA41 studi
- Baldwin Park, CA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA31 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Studi lain di Queens
- Kanker Payudara64 studi
- Kanker Paru Non-Sel Kecil49 studi
- Kanker Kolorektal31 studi
- Kanker Metastatik28 studi
- Kanker Ovarium28 studi
- Kanker Prostat27 studi
- Kanker (semua jenis)26 studi
- Kanker Endometrium25 studi
- Kanker Paru22 studi
- Mieloma Multipel20 studi
- Kanker Pankreas20 studi
- Karsinoma Sel Skuamosa Kepala dan Leher20 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.